New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients ...

A patient under Dr. Scott Roberts' care tested positive for SARS-CoV-2 for over 500 days due to severe immunocompromise. The FDA authorized pemivibart for preexposure prophylaxis in immunocompromised individuals, and IDSA updated its guidelines to recommend its use. Despite concerns about efficacy against new variants, pemivibart offers a new preventive option for high-risk patients.